Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Skinternal Medicine Case 7: Evaluation of Calcinosis and Tight Skin in Systemic Sclerosis

Description

The case discussed involves a patient in her 70s referred for evaluation of tight skin and calcinosis associated with systemic sclerosis. Her symptoms began in her 20s and progressed to include joint pain and limited mobility. Importantly, she did not manifest key symptoms typical of systemic sclerosis, such as sclerodactyly, Raynaud's phenomenon, or specific antibody positivity. Instead, her skin remained mobile, which is contrary to the features of systemic sclerosis. Upon examination and imaging, significant joint destruction suggested psoriasis and ankylosing spondylitis rather than systemic sclerosis. A large punch biopsy indicated a non-sclerotic pathology with abnormal deposition of calcium, raising the suspicion of familial tumoral calcinosis. This condition, characterized by large calcified masses and hyperphosphatemia, was confirmed through laboratory findings showing elevated FGF23 levels. The management plan included dietary phosphate restriction, phosphate binders, and medications targeting interleukin-1 to control inflammation and pain. Ultimately, the patient's ongoing management was optimized after consultation with the NIH, resulting in improved symptoms and normalization of inflammatory markers, emphasizing the importance of considering alternative diagnoses in cases of atypical calcinosis.

View more

Conclusions

  • The patient does not have systemic sclerosis despite initial diagnoses due to lack of characteristic symptoms and laboratory findings.
  • Calcinosis in this patient presents differently than the calcinosis typical of systemic sclerosis, suggesting alternative diagnoses.
  • Elevated inflammatory markers were noted; this may be due to underlying conditions rather than systemic sclerosis.
  • The workup reveals hyperphosphatemia, which led to a diagnosis of hyperphosphatemic familial tumoral calcinosis.
  • Treatment for the patient involves managing hyperphosphatemia and addressing pain from calcinosis, potentially using anti-interleukin-1 therapies.
  • van den Hoogen et al. 2013 Classification Criteria for Systemic Sclerosis. An ACR/EULAR Collaborative Initiative. Arthritis and Rheumatism. 2013. 65(11): 2737-2747.
  • Reiter N et al. Calcinosis cutis Part I. Diagnostic pathway. J Am Acad Dermatol. 2011;65:1-12.
  • Sprecher E. Familial Tumoral Calcinosis: From Characterization of a Rare Phenotype to the Pathogenesis of Ectopic Calcification. JID. 2010. 130:652-660.
  • Boyce AM et al. Hyperphosphatemic Tumoral Calcinosis: Pathogenesis, Clinical Presentation, and Challenges in Management. 2020. Front. Endocrinol. 11:293.
  • Ramnitz et al. Phenotypic and genotypic characterization and treatment of a cohort with familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome. J Bone and Mineral Research. 2016. 31(10): 1845-1854.
  • Favia G et al. Hyperphosphatemic Familial Tumoral Calcinosis: Odontostomatologic Management and Pathological Features. Am J Case Rep. 2014; 15: 569-575.
  • Ziegler SG et al. Disorders and Mechanisms of Ectopic Calcification. Genetics of Bone Biology and Skeletal Disease. 2018. Second Edition.
  • Doneray H et al. The successful treatment of deep soft-tissue calcifications with topical STS and acetazolamide in a boy with FTC due to a novel mutation in FGF23. J Clin Res Pediatr Endo. 2022. 14(2):239-243.